John F. Hamilton 251 60 311 2 0 313 0 780 Digene Corp.** Charles M. Fleischman 323 151 474 0 0 474 308 4,427 Discovery Laboratories Inc...John F. Milligan 331 245 576 0 1,450 2,026 5,330 5,954 GTC Biotherapeutics Inc

419 160 579 9 John F. Milligan Gilead Sciences Inc...250 63 313 63 John F. Hamilton DepoMed Inc

John F. Hamilton 217 50 267 3 0 270 43 0 Digene Corp.** Charles M. Fleischman (17) 296 107 403 0 2,536 2,939 1,385 492 Discovery Laboratories Inc

235 35 270 75 Jay M. Moyes (53) Myriad Genetics Inc.** 208 61 269 76 John F. Hamilton DepoMed Inc

252 0 252 84 John F. Hamilton DepoMed Inc

John F. Hamilton 211 40 251 2 0 253 199 331 Digene Corp.** Charles M. Fleischman 274 150 424 0 61 485 1,451 9,981 Discovery Partners Intern

The company also has John F. Warner, vice president, research and technology

A fifth entry, Jeffrey Whitsett, at the University of Cincinnati, is poised to join this line-up, said cell biologist John F. Engelhardt, James Wilson's collaborator at the University of Pennsylvania

John F. Beary III, senior vice president for science and technology at PMA, said the burgeoning biotechnology industry had flooded FDA's Center for Biologics, Evaluation and Research (CBER

Branscomb is an Albert Pratt Public Service Professor at the John F. Kennedy School of Government at Harvard University

Also, John F. Chappell, founder and president of Plexus Ventures Inc., an investment firm, has been elected to the board of the Menlo Park, Calif., company, which is developing treatments for disorders and diseases of the brain and central nervous system

Ribi ImmunoChem Research Inc. (NASDAQ:RIBI), a Hamilton, Mont., developer of immunostimulants, has elected John F. Chappell to its board